期刊文献+

万古霉素致不良反应41例文献分析 被引量:7

Literature Analysis in 41 Patients of Adverse Drug Reactions Caused by Vancomycin
在线阅读 下载PDF
导出
摘要 目的:分析万古霉素致药物不良反应(ADR)的原因与特点,为临床规范合理使用万古霉素提供参考。方法方法:利用万方数据库,检索"万古霉素""不良反应"为检索词,剔除同一病例不同文献的重复的以及病例资料不全的文献,筛选出41例万古霉素致不良反应病例文献,并对其ADR发生的原因和特点作了分析。结果:万古霉素导致不良反应主要有变态反应(48.78%)、肾毒性(14.63%)、白细胞减少(12.20%)等;另有肝损害、第8脑神经、皮肤黏膜综合征、四肢颤抖等也有报道。结论:万古霉素致不良反应较多,应规范其用法用量及对可能出现的不良反应进行监测。 Objective: To analyze the causes and characteristics of adverse drug reactions(ADRs) caused by Vancomycin and to Provide a reference for clinical rational use of vancomycin. Methods: The articles published in Wanfang Database are retrieved by searching the word Vancomycin and adverse drug reaction. And are eliminated the repeated reports in different literature and the case whose data are not enough comprehensive. A total of 41 patients of vancomycin cases of adverse reactions are selected to analyze and statistics to make finally. Results: The adverse drug reactions of the use of vancomycin mainly include allergy reaction (48.78%), kidney damage (14.63%) and leukopenia (12.20%). In addition,cases about liver danaage, the eighth cranial nerves damage, a syndrome of skin and mucosa, limb tremors have been also reported. Conclusion: Since the adverse drug reactions of vancomycin are general, the usage and dosage of vancomycin should be regulated and its possible adverse reactions should be monitored timely.
出处 《抗感染药学》 2017年第4期804-807,共4页 Anti-infection Pharmacy
基金 中山市科学技术基金项目(编号:2014A1FC151)
关键词 万古霉素 不良反应 文献分析 Vancomycin ADR literature analysis
作者简介 邱雄泉(1972-),男,主任药师 [通信作者]陈晓坚(1990-),女,在读硕士研究生,药师[联系电话]:13802668925 E-mail:joeky@163.com
  • 相关文献

参考文献5

二级参考文献21

  • 1陈燕琴,宋萍.万古霉素静滴致小儿红人综合征1例报道[J].浙江预防医学,2009,21(2). 被引量:7
  • 2卫生部合理用药专家委员会组织.中国医师药师临床用药指南[M].重庆:重庆出版社,2009:711.
  • 3Arias CA,Murray BE.Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J].N Engl J Med,2009,360(5):439-443.
  • 4Clinical and Laboratory Standads Institute.Performance Standards for Antimicrobial Susceptibility Testing[S].Fifteenth Informational Supplement,2010,M100-S20 Vol 30 No.1.
  • 5Clinical and Laboratory Standads Institute Performance Standards for Antimicrobial Susceptibility Testing[S].Fifteenth Informational Supplement,2010,M100-S20-U Vol 30 No 15.
  • 6Clinical Laboratory Standard Institute.Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria[S].Approved Guideline M45-A,Vol.26 No.19,2006.
  • 7Wang P,Hu FP,Xiong ZZ,et al.Susceptibility of ESBL-Producing nterobacteriaceae with the New CLSI Breakpoints[J].J Clin Microbiol,2011,49(6):3127-3131.
  • 8Yang Q,Wang H,Sun H,et al.Phenotypic and genotypic characterization of Enterobacteriaceae with decreased susceptibility to carbapenems:results from large hospital-based surveillance studies in China[J].Antimicrob Agents Chemother,2010,54(1):573-577.
  • 9Wang H.Guo P,Sun HL,et al.Molecular epidemiology of clinical isolates of carbapenem-resistant Acinerobacter spp from Chinese hospitals[J].Antimicrob Agents Chemother.2007,51(11):4022-4028.
  • 10Myers AL, Gaedigk A, Dai H, et al. Defining risk factors for red man syndrome in children and adults. Pediatr Infect Dis J, 2012, 31(5): 464-468.

共引文献681

同被引文献103

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部